alpha-1 AT = alpha-1 antitrypsin; ANA = antinuclear antibodies; SMA = smooth muscle antibodies; anti-LKM1 = antibodies to liver/kidney microsome type 1; AMA = antimitochondrial antibodies ...
Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales. Read why I rate KRYS ...
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Mereo Biopharma Group Plc (MREO) has received a new Buy rating, initiated by LifeSci Capital analyst, Cory Jubinville, PhD.Don't Miss Our ...
Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company, recently shared his outlook for the stock ...
Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the stock, Marketbeat Ratings reports. Three ...
WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat ...
Insider Monkey on MSN4d
Will Vertex Pharmaceuticals Incorporated (VRTX) Make You Rich In 2025?IgA nephropathy (from the recent acquisition of Alpine Immune Sciences), and alpha-1 antitrypsin disease. Vertex has had a ...
Fintel on MSN5d
LifeSci Capital Initiates Coverage of Mereo BioPharma Group plc - Depositary Receipt () (MREO) with Outperform Recommendationalvelestat for the treatment of severe Alpha-1 antitrypsin deficiency (AATD), which is being investigated in an ongoing Phase ...
Geode Capital Management LLC boosted its position in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 4.5% during the third quarter, according to the company in its most recent filing with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback